Homepage Top Section2

The FDA designation for the Tecentriq chemo combination is for TNBC patients whose condition is unresectable locally advanced or metastatic and whose disease expresses the PD-L1 protein, as

The analysis, which is part of the 3b Expedition-8 study, assessed the safety and efficacy of Mavyret in treatment-naïve chronic hepatitis C virus (HCV) patients with compensated cirrhosis

Mirum Pharmaceuticals is focused on the development of an approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions. Maralixibat is under development for

Lorbrena is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) to treat patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least

The approval paves way for the use of Hyrimoz in the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older,

For Nexium, which is used in the treatment of gastroesophageal reflux disease, ulcers, and Zollinger-Ellison syndrome, Grünenthal will be acquiring the prescription medicine rights in Europe, which will

Karo Pharma develops and markets products for pharmacies and also directly to the healthcare sector. The specialty pharma company is said to have a strong presence in the

The 52-week, randomized, double-blind, placebo-controlled study investigated the LDL-C lowering efficacy and the safety and tolerability of bempedoic acid 180mg in comparison to placebo. It was carried out

The regulator issued a complete response letter (CRL) over the chemistry, manufacturing and controls (CMC) prior-approval supplement (PAS) for the Eylea pre-filled syringe. Eylea injection is a vascular